Olympus Corp

XMUN:OLY1

Revenue Guidance Cut: Olympus lowered its revenue outlook by 2% on a constant currency basis, mainly due to ship holds in the SIS division and commercial execution issues in the GIS division, especially in the U.S.

Q3 U.S. Weakness: U.S. GI performance was flat in Q3, which management attributes to poor pipeline conversion and commercial execution, not to product competitiveness. Steps have been taken to improve execution, and growth is expected to return in Q4.

China Recovery: After multiple quarters of double-digit declines, China saw 6% growth in Q3. Management expects gradual but continued improvement due to strategic changes and new leadership.

FDA Inspections & Ship Holds: Inspections led to observations and product holds, impacting cost and revenue. Most product holds are expected to resolve in Q4, but 30% remain under remediation.

Margin & Cost Guidance Unchanged: The company reiterated its goal of 100+ basis points of annual margin improvement and mid-single-digit revenue growth, with no reset of margin or gross margin targets despite one-off impacts.

Restructuring Costs: Restructuring costs were revised up to JPY 31 billion (from JPY 12 billion) but are mostly provisioned this fiscal year. The expected JPY 24 billion cost savings remain unchanged.

Leadership & Quality Focus: Management emphasized patient safety and proactive quality actions, rejecting the notion of a fundamental cultural problem in the SIS business.